Form 8-K - Current report:
SEC Accession No. 0001213900-21-009265
Filing Date
2021-02-16
Accepted
2021-02-16 08:30:28
Documents
7
Period of Report
2021-02-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea135663-8k_silopharma.htm 8-K 31330
2 MASTER LICENSE AGREEMENT, DATED FEBRUARY 12, 2021, BY AND BETWEEN THE COMPANY AN ea135663ex10-1_silopharma.htm EX-10.1 445021
3 LETTEROF INTENT, DATED FEBRUARY 12, 2021, BY AND BETWEEN THE COMPANY AND AIKIDO ea135663ex10-2_silopharma.htm EX-10.2 11197
4 GRAPHIC ex10-1_001.jpg GRAPHIC 7089
5 GRAPHIC ex10-1_002.jpg GRAPHIC 4760
6 GRAPHIC ex10-1_003.jpg GRAPHIC 3325
7 GRAPHIC ex10-2_001.jpg GRAPHIC 4213
  Complete submission text file 0001213900-21-009265.txt   516258
Mailing Address 560 SYLVAN AVE SUITE 3160 ENGLEWOOD CLIFFS NJ 07632
Business Address 560 SYLVAN AVE SUITE 3160 ENGLEWOOD CLIFFS NJ 07632 (718) 400-9031
Silo Pharma, Inc. (Filer) CIK: 0001514183 (see all company filings)

EIN.: 462137136 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-54872 | Film No.: 21632822
SIC: 2300 Apparel & Other Finishd Prods of Fabrics & Similar Matl